Back

State of the art in Empaglifozin in cardiovascular outcomes.

30 August 2016 (14:00 - 14:18)
Organised by:
Congress Presentation Part of: A perspective on the effects of Empaglifozin in cardiovascular outcomes Drug therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

4 More presentations in this session

Presentation thumbnail
Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
Doctor P. Monteiro (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes according to LDL cholesterol levels in EMPA-REG OUTCOME
Doctor G. Langslet (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
Professor D. Fitchett (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Future direction for research in Empaglifozinon heart failure treatment.
Associate Professor P. Sarafidis (Thessaloniki, GR)
Slides Video

Access the full session

Session thumbnail
A perspective on the effects of Empaglifozin in cardiovascular outcomes

The Event

Event poster

ESC Congress 2016

30 August 2016 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources